Abstract: The image encoding and decoding method and apparatus based on a periodicity on phase signal are disclosed. One embodiment on an encoding an image, the method comprising: generating a prediction signal for an input signal, calculating an initial residual signal, which is a difference value between the input signal and the prediction signal, generating a transformed residual signal by transforming a value of the initial residual signal to have a size value within a preset range, and encoding the transformed residual signal, wherein the transformed residual signal is generated based on a period of a signal, wherein the preset range is a range of the period of the signal.

Abstract: A coil component is disposed. The coil component according to an aspect of the present disclosure includes: a body; a coil portion disposed in the body; an external electrode portion including a first metal layer disposed on the body, and connected to the coil portion; and a surface insulating layer disposed on the body to cover a first region of the first metal layer and open a second region of the first metal layer. Surface roughness of an interface of the first region of the first metal layer with the surface insulating layer is higher than surface roughness of an outer surface of the second region of the first metal layer.

Abstract: An electrical terminal connector, a substrate support, and a substrate processing apparatus are provided. The electrical terminal connector includes a housing unit installed by penetrating through a heater cup and having a housing ring, and a terminal connection unit installed to reciprocate within the housing unit and having a terminal connection portion to or from which an electric terminal is attached and detached. The terminal connection portion is variable so that the electric terminal is insertable when the terminal connection portion is separated from the housing ring and the electric terminal is fixed when the terminal connection portion is inserted into the housing ring together with the inserted electric terminal.

Abstract: A semiconductor device includes a substrate having a first region and a second region, first active fins that extend in a first direction in the first region, second active fins that extend in the first direction in the second region, a first field insulating layer between the first active fins and that extend in a second direction, a second field insulating layer between the second active fins and extending in the second direction, a gate line that extends in the second direction on the second field insulating layer, the gate line linearly along with the first field insulating layer, a gate isolation layer between the first field insulating layer and the gate line, and gate spacers that extend in the second direction, the gate spacers in contact with both sidewalls of each of the first field insulating layer, the gate line, and the gate isolation layer.

Abstract: The disclosure relates to a method of training an artificial neural network so that a first artificial neural network is trained based on a plurality of training data including a first feature and a second feature that has a correlation with the first feature and depends on the first feature.

Abstract: The present invention relates to a sea urchin-derived peptide and a use thereof and more specifically, to a use of the sea urchin-derived peptide for preventing or treating a disease associated with the V1B receptor of Echinotocin, which is a peptide derived from sea urchins. The Echinotocin according to the present invention was found to have an effect of inducing activation of the V1B receptor, which is a type of vasopressin receptors. The V1B receptor, which is a vasopressin receptor, exists in the anterior pituitary gland and the hippocampus CA2 region and is known to increase intracellular calcium concentration and to be involved in a response to stress and sociality. Therefore, the Echinotocin according to the present invention can find various applications in the field of preventing, alleviating, or treating V1B receptor-related diseases.

Abstract: The present invention relates to a controller of a camera module capable of simplifying a measurement system and reducing cost by having a frequency response measurement function. A controller of camera module according to an embodiment, in a driving mode, preprocesses an actuator position value signal sensed by a Hall sensor to output to a measurement equipment, a target position value, arithmetic processes a target position value, an actuator position value signal and a disturbance signal supplied from the measurement equipment to output an error value signal to the measurement equipment, and generates an actuator driving signal that compensates for the error value signal to drive an actuator.

Abstract: An anode for a secondary battery is provided, the anode for a secondary battery including: an anode current collector; a first anode mixture layer formed on at least one surface of the anode current collector, and including a first silicon-based active material and a first conductive material; and a second anode mixture layer formed on the first anode mixture layer, and including a second silicon-based active material and a second conductive material, wherein a content of the first silicon-based active material in the first anode mixture layer is lower than a content of the second silicon-based active material in the second anode mixture layer, and a Radial Breathing Mode (RBM) peak is observed in a Raman spectrum obtained from a surface of the second anode mixture layer.

Abstract: A semiconductor device includes a substrate having a first region and a second region, first active fins that extend in a first direction in the first region, second active fins that extend in the first direction in the second region, a first field insulating layer between the first active fins and that extend in a second direction, a second field insulating layer between the second active fins and extending in the second direction, a gate line that extends in the second direction on the second field insulating layer, the gate line linearly along with the first field insulating layer, a gate isolation layer between the first field insulating layer and the gate line, and gate spacers that extend in the second direction, the gate spacers in contact with both sidewalls of each of the first field insulating layer, the gate line, and the gate isolation layer.

Abstract: The present invention relates to squid-derived peptides and uses thereof and, more specifically, to uses of squid-derived peptides squidtocin and pro-sepiatocin for prevention or treatment of V1B receptor-related diseases. It has been confirmed that the squidtocin and pro-sepiatocin according to the present invention have an effect of inducing activation of a V1B receptor which is a type of vasopressin receptor. The V1B receptor which is a type of vasopressin receptor is present in the anterior pituitary and in the hippocampal CA2 region, and it is known that the V1B receptor increases intracellular calcium concentration and is involved in response to stress and sociality. Accordingly, the squidtocin and the pro-sepiatocin according to the present invention can be used in various ways in the field of prevention, amelioration, or treatment of V1B receptor-related diseases.

Abstract: A glass article used as a cover glass of a flexible display device has values of indices consistent with results of a pen drop test and excellent impact resistance characteristics.

Abstract: A coil component includes a body having one surface and the other surface, opposing each other, both lateral surfaces respectively connecting the one surface and the other surface and opposing each other, and both end surfaces respectively connecting the both lateral surfaces and opposing each other; a coil unit disposed in the body; a first external electrode and a second external electrode, respectively connected to the coil unit and disposed to be spaced apart from each other on the one surface of the body; and a first insulating layer covering the other surface of the body, the both lateral surfaces of the body, and the both end surfaces of the body.

Abstract: A pharmaceutical composition containing a compound of Formula 1 or Formula 2 below or a pharmaceutically acceptable salt thereof. The composition is suitable for preventing or treating RON-mutation-associated biliary tract cancer. The pharmaceutical composition can be applied to a biliary tract cancer patient having a RON mutation. Particularly, the pharmaceutical composition can be effectively used for treating a biliary tract cancer patient who is resistant to cetuximab, which is conventionally used for cancer treatment, and who has mutation at RONA 155, RON?160 or RON?165.

Abstract: The present invention relates to a biomarker for predicting susceptibility to an MET inhibitor, and a use thereof, and more specifically, the present invention provides a method for predicting susceptibility to the MET inhibitor. According to the present invention, the present invention has an excellent effect of predicting susceptibility to the MET inhibitor for stomach cancer or lung cancer, and thus the present invention may be usefully employed for treating stomach cancer or lung cancer.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d' Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d' Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.

Abstract: The present disclosure relates to a new biomarker for predicting susceptibility to an EGFR-targeted agent and a use thereof, and more particularly, provides a biomarker for predicting susceptibility to an EGFR (Epidermal Growth Factor Receptor)-targeted agent, comprising a RON (Recepteur d'Origine Nantais) gene; a composition for predicting susceptibility to the EGFR-targeted agent, comprising an agent which measures a gene expression level of the biomarker; or an expression or activity level of a protein thereof; a composition for enhancing the susceptibility to the EGFR-targeted agent, comprising an inhibitor of the expression of the gene or the expression or activity of the protein of the gene as active ingredients; a kit for predicting the susceptibility to the EGFR-targeted agent, comprising the composition; and a method for predicting the susceptibility to the EGFR-targeted agent.

Abstract: The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.

Abstract: The present invention relates to a method for determining sensitivity to a simultaneous inhibitor against poly ADP ribose polymerase (PARP) and Tankyrase. According to the present invention, a colorectal treatment effect can be maximized by sorting patients having sensitivity to the simultaneous inhibitor against PARP and Tankyrase.